New once daily formulation for trospium in overactive bladder - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue International Journal of Clinical Practice Année : 2010

New once daily formulation for trospium in overactive bladder

Christopher Chapple
  • Fonction : Auteur correspondant
  • PersonId : 895477

Connectez-vous pour contacter l'auteur

Résumé

Aims To examine the relative efficacy and safety of trospium 20mg bid and 60 mg extended release formulations and position this drug against other antimuscarinic agents Methods Data were identified on the pharmacology and pharmacokinetics of trospium chloride. Key publications on trospium 20 mg and 60 mg clinical studies in patients with overactive bladder (OAB) were identified and efficacy and safety compared between these formulations as well as other antimuscarinic agents. Results Trospium offers the principal advantage over other antimuscarinic agents that, as it is a quaternary amine, it does not cross the blood-brain barrier and is therefore less likely to cause central nervous system effects observed with several other agents. Moreover, with its minimal liver metabolisation, independent of the main cytochrome pathways, trospium has a low risk of drug-drug interaction in patients taking multiple pharmacological agents. Trospium 60 mg ER is as effective as trospium 20 mg bid in improving the key outcome parameters associated with OAB, but with a lower rate of dry mouth, the most common side-effect of these agents. Trospium has comparable efficacy and safety to the other antimuscarinic agents currently marketed. Good patient persistence with treatment has been reported with trospium. Conclusion There are currently a large number of antimuscarinic drugs on the market without clear evidence to distinguish one agent from another in terms of efficacy provided an adequate dose is used in the clinical setting. The new formulation of trospium is certainly worth considering as a pharmacological treatment of patients with OAB, particularly the elderly where one wants to avoid the potential for cognitive dysfunction.

Mots clés

Fichier principal
Vignette du fichier
PEER_stage2_10.1111%2Fj.1742-1241.2010.02493.x.pdf (254.6 Ko) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)
Loading...

Dates et versions

hal-00576628 , version 1 (15-03-2011)

Identifiants

Citer

Christopher Chapple. New once daily formulation for trospium in overactive bladder. International Journal of Clinical Practice, 2010, 64 (11), pp.1535. ⟨10.1111/j.1742-1241.2010.02493.x⟩. ⟨hal-00576628⟩

Collections

PEER
38 Consultations
263 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More